Member Info for technick

I look forward to seeing if there’s a new RNS each morning with this share, lots of news flow over the coming months. A lot of value building being done here in terms of intellectual property and approvals.

u696061, yes agree the communication has been very poor, to be fair it always has been with GDR over the 4 years I've held my investment, but they have delivered broadly in line with where they have said they would be. Here the lack of communication is down to lack of approvals, we are stymied until those come in. They will come in and this will explode with sales :)

https://uk.mobile.reuters.com/article/amp/idUKKBN27S1II?__twitter_impression=true

Testing will still be needed once vaccines are widely used. That’s because no inoculation is likely to work all the time, and immunity may not last. Health professionals will need to be regularly checked. The World Health Organization estimates there are some 60 million front-line medical staff globally. Test them once a week, and you need 3.1 billion tests a year, costing, at five dollars a pop, $15.6 billion.

Testing may also be needed where people are confined for long periods, such as air travel, especially during outbreaks. If just 10% of the roughly 4.1 billion passengers each year were tested, the annual cost would be $2 billion. That implies at least 3.5 billion tests a year, costing $17.6 billion.

cut an paste from the report but interesting headline figures for spending values in this sector.. IQAI have several products to multiply

1. 41% of responding life sciences companies invested between $20 million and $50 million in AI during 2019.
2. 21% spent more than $50 million on the emerging technology.
3. 50%-plus intend to keep spending this year as AI “moves from tactical improvements in efficiency to larger-scale, organization-wide projects,” Deloitte reports.
4. 46% seem to accept that the time window for enjoying a return on AI investment takes longer than they’d expected.

Opens the European market which is arguably larger as the US... yes that would shift us into another gear

Same pattern as the other day, not saying its US investors in the afternoon, but is it US investors in the afternoon? IB is a US business and will get much more visibility there than here. It's why I think a NASDAQ listing may happen, more scope for trading volume than over here although we don't do too badly!

I do see parallels which is why I'm invested in both. Covid aside, Genedrive has the opportunity to become a common point of care platform for qPCR. They've proved it now with a number of tests. I think however, they need a larger parent company and trade sale must be on the cards - but to be fair I've been saying that for a few years! For me it's about laying foundations and then building, the foundations are down and the business will be built, Covid has been a distraction but whilst here they need to deliver. They will, I'm confident.

the breadth of algorithms being deployed by IB is phenomenal, each gaining FDA approval which is not insignificant... The latest was an interesting partnership strategy as IB now proficient at the FDA process. Sales coming in now, the next 12 months is exciting. In terms of market cap, surely £100m-£200m with sales and a trade sale or NASDAQ float to exit...

Dream, with that weI can agree, we all watch with interest...

Dream, I've been a share holder there since the end of 2018. I have had to sit through the same nonsense of 'there's no product', 'where's the value', 'sell now'. And indeed I did, took advantage of the drop and am sitting happy when, after 12 months, more news did recently drop around as it happens, FDA approvals. So, same story, greta products, takes time for approvals, but when they come they open many doors. Hold tight.

Sneak, it's a tough call for the business. As I said, they were not in the same industry as NCYT in delivering high volume tests to the market, they were. DB has to be given some credit in having a strategy that separated the competition and attracted a large partner to the table. They have to get approvals first and the MC reflects that.

In terms of small contract, GDR are not a B2C company. They want to make large batches of tests and sell them to a few resellers. I'm still optimistic, but I release that's not a typical way of thinking. Glass half empty is still a glass half full.

Flying, I agree, a lot of us invested based on the non-covid tests, COVID has created a lot of noise but allowed the business to fund its main activities which was unexpected. I think it has probably distracted the team but opened a lot of doors and got Genedrive on the radar of a few US companies now.

RB, my understanding is the number of symptomatic cases of COVID-19 per 1000 participants at 7 days following the second vaccine and that this was 90% lower in those that received the vaccine compared to those that received the placebo. We do not know what the effect on asymptomatic patients were. This suggests these people were not tested and the results is based on symptoms only!! Very poor.

I'm not sure but it looks to be 1-3 at at time?

Yes sorry immunising.

CE-IVD were given in May, approvals for US and India went in end of June. We are 4 and a bit months in to systems that were overloaded with over 1700 kits looking for approval. Unfortunately this has swamped the system. The choice will be whether the GDR kit provided advantages that provide a market now. I personally think that market is even bigger than it was and likely to be around longer than we initially thought.

Hold firm on your own research and due diligence, we may differ in views but that's ok. I believe in the product, the strategy and the direction of travel.

So many unanswered questions about the vaccine. No data on the longevity of protection, no data on whether it prevents infection and spread of infection and if its only symptoms that are suppressed, no data on performance in the most vulnerable groups since the only trials to date are in healthy 18-55 range - arguably the wrong group to be testing. And no data yet on whether suppressing the spread simply puts evolutionary pressure on a mutated genotype to spread, unencumbered by the vaccine and into a population now free to mix again.

No, testing needs will increase and time will show that.

Genedrive do need their brake now with approvals. I think there model of either high volume (US) or low resource (India) will shine through. Again their POC solution too should debut and perform better than the Optigene which has shown to have sensitivity issues in their trials.

Hold firm, LTHs time will come here.

Depends where the mutations occur. The Pfizer vaccine causes the muscles cell the artificial virus infects product lots of the spike protein. The body sees that as foreign and elicits an immune response creating antibodies that recognise the chemical signature (epitopes) on the protein surface. That depends on the structure of the protein. If the mutation or mutations change the way this protein is presented such as changing an amino acid, then the antibodies produced by the immune response may not recognise it and prevent the body from fighting the virus. Thats what happens with the common cold and influenza and why you get infected again and again and again and again and...

Wow, what a shame

He has to stay below 30% otherwise he has to buy the whole Company, he certainly wouldn't want to be in that position. Let's hope for some market normality today and a day where LSE doesn't have to turn off chat during trading hours...

There are a lot of questions that need answers before the vaccine can go live.

Firstly confirmation of the 90% effectiveness, this number was down to there being 8 more infection cases in the placebo group compared to the vaccinated group, the assumption is that the sample size was large enough for this to be statistically significant, the number could fall as a wider sample size throws up issues in different groups of patients.

Secondly, there is no indication of how long you are protected after vaccination.

Thirdly, the logistics of storage, transport and administration are significant because of the short life of the vaccine (pseudo virus) outside of -70/-80C.

Practically to vaccinate the population will take at least 12 months once the year picture of efficacy are known. During that time testing and isolation are the only viable ways to open the economy.

The overselling of covid stocks shows how much sentiment plays in the value of a share. DB's strategy to focus on countries outside of the UK may pay dividends in the long run, particularly countries with difficult infrastructures where testing may be here for many years to come and a simple all in one test will be key to providing test integrity.